Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-gamma Inhibitors.
Pemberton, N., Mogemark, M., Arlbrandt, S., Bold, P., Cox, R.J., Gardelli, C., Holden, N.S., Karabelas, K., Karlsson, J., Lever, S., Li, X., Lindmark, H., Norberg, M., Perry, M.W.D., Petersen, J., Rodrigo Blomqvist, S., Thomas, M., Tyrchan, C., Westin Eriksson, A., Zlatoidsky, P., Oster, L.(2018) J Med Chem 61: 5435-5441
- PubMed: 29852070 
- DOI: https://doi.org/10.1021/acs.jmedchem.8b00447
- Primary Citation of Related Structures:  
6FTN - PubMed Abstract: 
In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors. Starting from an HTS hit, potency and physicochemical properties could be improved to give compounds such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration. Compound 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.
Organizational Affiliation: 
Pharmaron Beijing Co., Ltd. , No. 6 Taihe Road, BDA , Beijing 100176 , P. R. China.